The Non-Antibacterial Effects of Azithromycin and Other Macrolides on the Bronchial Epithelial Barrier and Cellular Differentiation
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26052287 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Arni Asbjarnarson und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Health Sciences, University of Iceland, 101 Reykjavík, Iceland. Hauptthemen laut MEDLINE: Azithromycin, Macrolides, Cell Differentiation, Bronchi. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 104 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Doctoral Grants of The University of Iceland research fund, Doctoral Grants of the University of Iceland Research Fund, EpiEndo Pharmaceuticals.
Abstract (Originalsprache)
The respiratory epithelium maintains the barrier against inhaled harmful agents. When barrier failure occurs, as in several respiratory diseases, acute or chronic inflammation leading to destructive effects and exacerbations can occur. Macrolides are used to treat a spectrum of infections but are also known for off-label use. Some macrolides, particularly azithromycin (AZM), reduce exacerbations in chronic obstructive pulmonary disease (COPD), whereby its efficacy is thought to be due to its effects on inflammation and oxidative stress. In vitro data indicate that AZM reduces epithelial barrier failure, evidenced by increased transepithelial electrical resistance (TEER). Here, we compared the effects of macrolides on differentiation and barrier integrity in VA10 cells, a bronchial epithelial cell line for 14 and 21 days. Erythromycin, clarithromycin, roxithromycin, AZM, solithromycin, and tobramycin (an aminoglycoside) were analyzed using RNA sequencing, barrier integrity assays, and immunostaining to evaluate effects on the epithelium. All macrolides affected the gene expression of pathways involved in epithelial-to-mesenchymal transition, metabolism, and immunomodulation. Treatment with AZM, clarithromycin, and erythromycin raised TEER and induced phospholipid retention. AZM treatment was distinct in terms of enhancement of the epithelial barrier, retention of phospholipids, vesicle build-up, and its effect on gene sets related to keratinocyte differentiation and establishment of skin barrier.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Health Sciences, University of Iceland, 101 Reykjavík, Iceland.
- EpiEndo Pharmaceuticals, 102 Reykjavík, Iceland.
- Department of Laboratory Hematology, Landspítali-University Hospital, 101 Reykjavík, Iceland.
ORCID-Profile: Arni Asbjarnarson, Jon Petur Joelsson, Snaevar Sigurdsson, Michael J Parnham, Jennifer A Kricker, Thorarinn Gudjonsson
Förderung
- The Doctoral Grants of The University of Iceland research fund
- Doctoral Grants of the University of Iceland Research Fund
- EpiEndo Pharmaceuticals
Zitieren
APA
Asbjarnarson, A., Joelsson, J. P., Gardarsson, F. R., Sigurdsson, S., Parnham, M. J., Kricker, J. A., & Gudjonsson, T. (2025). The Non-Antibacterial Effects of Azithromycin and Other Macrolides on the Bronchial Epithelial Barrier and Cellular Differentiation. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26052287
Vancouver
Asbjarnarson A, Joelsson JP, Gardarsson FR, Sigurdsson S, Parnham MJ, Kricker JA, et al. The Non-Antibacterial Effects of Azithromycin and Other Macrolides on the Bronchial Epithelial Barrier and Cellular Differentiation. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26052287
BibTeX
@article{Asbjarnarson2025,
author = {Asbjarnarson, Arni and Joelsson, Jon Petur and Gardarsson, Fridrik R and Sigurdsson, Snaevar and Parnham, Michael J and Kricker, Jennifer A and Gudjonsson, Thorarinn},
title = {The Non-Antibacterial Effects of Azithromycin and Other Macrolides on the Bronchial Epithelial Barrier and Cellular Differentiation},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26052287}
}
EUVIMED